Drugs that contain Thalidomide
1. Thalomid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143283 | BRISTOL-MYERS | Methods for treating blood-born tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US7723361 | BRISTOL-MYERS | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US6235756 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar, 2013
(11 years ago) | |
| US5629327 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
May, 2014
(9 years ago) | |
| US7435745 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
Nov, 2017
(6 years ago) | |
| US6561976 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8589188 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6908432 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8204763 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US7874984 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6045501 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8626531 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6869399 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7959566 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7141018 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6755784 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6561977 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6315720 | BRISTOL-MYERS | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
| US8315886 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7230012 | BRISTOL-MYERS | Pharmaceutical compositions and dosage forms of thalidomide |
Dec, 2023
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 23, 2013 |
Market Authorisation Date: 16 July, 1998
Treatment: Use of thalomid (thalidomide) for the treatment of multiple myeloma; Use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma; Use in co...
Dosage: CAPSULE;ORAL
How can I launch a generic of THALOMID before it's drug patent expiration?
More Information on Dosage
THALOMID family patents
